PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,491,480 | -23.1% | 54,000 | -34.0% | 0.05% | -38.6% |
| Q1 2022 | $1,939,000 | -56.6% | 81,873 | -37.3% | 0.09% | -64.2% |
| Q4 2021 | $4,464,000 | +397.7% | 130,517 | +553.0% | 0.25% | +602.9% |
| Q2 2021 | $897,000 | -30.1% | 19,986 | -59.7% | 0.04% | -14.6% |
| Q1 2021 | $1,284,000 | +66.1% | 49,579 | +29.3% | 0.04% | +5.1% |
| Q4 2020 | $773,000 | +70.3% | 38,341 | +65.1% | 0.04% | +25.8% |
| Q3 2020 | $454,000 | -47.9% | 23,216 | -53.0% | 0.03% | -42.6% |
| Q2 2020 | $872,000 | – | 49,359 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |